Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.57 +0.64 (+1.31%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

Why Novo Nordisk Stock Eked Out a Win on Monday ↗

June 09, 2025

Via The Motley Fool

Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punch ↗

June 09, 2025

The company is planning to soon begin combination studies, testing two of its drugs in weight loss.

Via Investor's Business Daily

Topics Bankruptcy

Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy ↗

June 09, 2025

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly.

Via Benzinga

Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock? ↗

June 08, 2025

Via The Motley Fool

Topics Supply Chain

With Novo Nordisk's CEO Out, Wall Street Wants an American Leader

June 07, 2025

With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?

Via MarketBeat

3 Health Care Stocks With Whale Alerts In Today's Session ↗

May 30, 2025

Via Benzinga

Veru's Enobosarm Shows Muscle In Wegovy Combo Trial ↗

May 28, 2025

Via Benzinga

This Monster Growth Stock Is Up 167% in the Past Year and Disrupting the Healthcare Space ↗

June 07, 2025

Via The Motley Fool

Topics Intellectual Property

The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching. ↗

June 06, 2025

Amgen is hoping to take on Eli Lilly and Novo Nordisk with a potential monthly shot, MariTide.

Via Investor's Business Daily

Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say ↗

June 06, 2025

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular degeneration, and kidney cancer.

Via Benzinga

Novo Nordisk Stock: Is It Still a Smart Buy? ↗

June 06, 2025

Via The Motley Fool

Should You Invest $1,000 in Eli Lilly today? ↗

June 05, 2025

Via The Motley Fool

What's Going On With Novo Nordisk Shares Today? ↗

June 03, 2025

Shares of Novo Nordisk Inc. (NYSE: NVO) are trading lower Tuesday after a new study raised concerns about a potential link between GLP-1 weight loss drugs like Ozempic and an increased risk of kidney...

Via Benzinga

Florida Rep. Scott Franklin Bought Up to $15K Worth of Union Pacific Stock ↗

June 03, 2025

Via Benzinga

Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target ↗

June 02, 2025

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce.

Via Benzinga

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock with Reasonable Valuation ↗

May 31, 2025

NOVO-NORDISK (NYSE:NVO) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks.

Via Chartmill

2 Top Stocks to Buy With Less Than $100 ↗

May 30, 2025

Via The Motley Fool

2 Beaten-Down Stocks to Buy on the Dip ↗

May 30, 2025

Via The Motley Fool

Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly ↗

May 29, 2025

Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position?

Via Investor's Business Daily

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Candidate for Value Investors ↗

May 28, 2025

NOVO-NORDISK (NYSE:NVO) offers strong profitability, solid growth, and reasonable valuation, making it a compelling choice for value investors. Its financial health and industry-leading margins add...

Via Chartmill

Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market? ↗

May 28, 2025

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

May 27, 2025

Via Benzinga

3 Surprising Stocks That Have More Than Doubled in 2025 ↗

May 27, 2025

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would have predicted.

Via The Motley Fool

Topics Government

Why Novo Nordisk Stock Just Popped ↗

May 27, 2025

President Trump has good news for Novo Nordisk investors, and more may be on the way.

Via The Motley Fool

Topics Government World Trade

"If Walmart Is Under Pressure to Raise Prices, It's Going to Have Broader Effects on the Economy." ↗

May 27, 2025

Via The Motley Fool

Topics Earnings Economy World Trade

8 Health Care Stocks With Whale Alerts In Today's Session ↗

May 23, 2025

Via Benzinga

Analysts Think These Stocks Could More Than Double in Value

May 23, 2025

Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.

Via MarketBeat

Topics World Trade

Hims & Hers Stock Drops After Evernorth Announces Cheaper Pricing For Weight-Loss Drugs: Retail’s Dull ↗

May 22, 2025

Truist noted on Thursday that the $200/month price point is "highly attractive compared to other price points in the market," including Hims & Hers' compounded Semaglutide, Wegovy, and Liraglutide...

Via Stocktwits

Novo Nordisk To Sell Wegovy For $199 A Month As Compounding Ban Nears: Retail’s Bullish ↗

May 22, 2025

The offer will be valid through June 30 and aims to encourage patients who previously used compounded versions of the drug to move to Wegovy.

Via Stocktwits

Did Eli Lilly Just Say Checkmate to Novo Nordisk? ↗

May 22, 2025

Via The Motley Fool

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

All News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today